利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

42 条记录 (耗时 0.016 秒)

    Gene examination method for judging the onset risk of glaucoma
    4.
    发明申请
    Gene examination method for judging the onset risk of glaucoma 审中-公开
    用于判断青光眼发病风险的基因检查方法

    公开(公告)号：US20050170353A1

    公开(公告)日：2005-08-04

    申请号：US10509595

    申请日：2003-03-19

    申请人： Kaoru Asano ,  Takayuki Takahata ,  Shigehiro Numada ,  Akinori Masago ,  Yasuhiro Kouchi

    发明人： Kaoru Asano ,  Takayuki Takahata ,  Shigehiro Numada ,  Akinori Masago ,  Yasuhiro Kouchi

    IPC分类号： C12Q1/68 ,  G01N33/68

    CPC分类号： G01N33/6893 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N33/6887 ,  G01N2800/168

    摘要： To provide a gene examination method for predicting the onset risk of glaucoma based on the relation between a glaucoma-associated gene and the onset of glaucoma, the onset of glaucoma in future is predicted by using as an indication mutations in the gene region involving the code region and/or the upstream region of a glaucoma-associated gene. In the base sequence represented by SEQ ID NO:1, mutation(s) in at least one of the following positions are detected, i.e., the 194-, 199-, 324-, 1051-, 1084-, 1627-, 1685-, 1756-, 1853-, 2830-, 3371-, 4037- and 4364-positions.

    摘要翻译： 为了提供基于青光眼相关基因与青光眼发生之间的关系来预测青光眼的发病风险的基因检查方法，通过使用涉及代码的基因区域中的指示突变来预测未来的青光眼发作 区域和/或青光眼相关基因的上游区域。 在由SEQ ID NO：1表示的碱基序列中，检测至少一个以下位置的突变，即194-，199-，324-，1051-，1084-，1627-，1685- ，1756-，1853-，2830-，3371-4037-和4364-位。

    Intraocular pressure-regulated early genes and uses thereof
    7.
    发明申请
    Intraocular pressure-regulated early genes and uses thereof 有权
    眼内压调节的早期基因及其用途

    公开(公告)号：US20080305103A1

    公开(公告)日：2008-12-11

    申请号：US12154396

    申请日：2008-05-22

    申请人： H. Uri Saragovi

    发明人： H. Uri Saragovi

    IPC分类号： A61K39/395 ,  A61K38/16 ,  G01N33/68 ,  C12Q1/68 ,  C07H21/04 ,  A61P27/06

    CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K14/47 ,  C07K16/30 ,  C07K2317/76 ,  G01N33/5308 ,  G01N2800/168

    摘要： The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or α2 macgroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or α2 macgroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or α2 macgroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.

    摘要翻译： 本发明涉及通过调节由高眼内压或α2巨球蛋白给药介导的基因表达变化来治疗青光眼和青光眼相关病症的方法。 使用药物组合物治疗青光眼，视网膜神经节细胞（RGC）死亡和慢性高眼压症，其包括抑制眼内压调节的早期基因（IPREG）或其高眼内压上调的基因产物的表达或活性的物质 或α2巨球蛋白给药和/或增加由高眼内压或α2巨溴蛋白给药下调的IPREG或其基因产物的表达或活性。 本发明还涉及通过测量IPREG蛋白的表达水平来鉴定IPREG的方法和测试个体中慢性眼变性和RGC应激发作的方法。

    SYSTEMS AND METHODS FOR DETERMINING RETINAL GANGLION CELL POPULATIONS AND ASSOCIATED TREATMENTS
    10.
    发明申请
    SYSTEMS AND METHODS FOR DETERMINING RETINAL GANGLION CELL POPULATIONS AND ASSOCIATED TREATMENTS 审中-公开

    公开(公告)号：US20180020908A1

    公开(公告)日：2018-01-25

    申请号：US15643402

    申请日：2017-07-06

    申请人： The Regents of the University of California

    发明人： Felipe A. Medeiros ,  Robert N. Weinreb ,  Linda M. Zangwill

    IPC分类号： A61B3/00 ,  G01N33/68 ,  A61B3/10

    CPC分类号： A61B3/0025 ,  A61B3/1005 ,  A61B3/102 ,  G01N33/6893 ,  G01N2800/168 ,  G01N2800/56

    摘要： A new combined index of structure and function (CSFI) for staging and detecting glaucomatous damage is provided. An observational study including 333 glaucomatous eyes (295 with perimetric glaucoma and 38 with preperimetric glaucoma) and 330 eyes of healthy subjects is described. All eyes were tested with standard automated perimetry (SAP) and spectral domain optical coherence tomography (SDOCT) within 6 months. Estimates of the number of retinal ganglion cells (RGC) were obtained from SAP and SDOCT and a weighted averaging scheme was used to obtain a final estimate of the number of RGCs for each eye. The CSFI was calculated as the percent loss of RGCs obtained by subtracting estimated from expected RGC numbers. The performance of the CSFI for discriminating glaucoma from normal eyes and the different stages of disease was evaluated by receiver operating characteristic (ROC) curves. The mean CSFI, representing the mean estimated percent loss of RGCs, was 41% and 17% in the perimetric and pre-perimetric groups, respectively (P